$16.96−0.32 (−1.85%)
At close: Oct 1, 2026, 4:00 PM ET
Janux Therapeutics Inc · Overview
Industry: Drugs · see every company filed here →
Janux Therapeutics Inc scores 60/100. Solid. Strongest on value and financial health, growth is the soft spot versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value94
Quality48
Health90
Growth7
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueAQualityDHealthAGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
—
no P/E on file
P/B
1.1×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
103.7×
price to fiscal 2025 sales
ROE
−11%
TTM through Jun 30, 2026
Operating margin
−1576.7%
fiscal 2025, before interest and tax
Net margin
—
no net margin on file
Current ratio
16.35
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 3y
—
needs five years of positive earnings
Market cap
$1.0B
small cap
Div yield
0.00%
reinvests all
52-wk range
12.12 – 35.34
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ~ Drawdown Context
- ✕ Reversal Evidence
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC−15%
Technical Analysis
Mixed short-term signalvs 50-day−0.6%
vs 200-day+13.2%
RSI (14)48
News & Insights
Headlines are on the News tab.Dividends
0.00% yield
Pays no dividend. Every dollar of profit is reinvested into the business.
Ownership
100% institutional
13F flows & insider trades land here.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in p…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold JANX, and at what weight. Everything else on this page stays open.Create a free account